Intellia Therapeutics, Inc. Q2 2026 Earnings Recap

Intellia shares jumped 8.8% following Q2 results, driven by compelling Phase III data on lonvo-z for hereditary angioedema and renewed momentum in the ATTR program, as clinical holds were lifted and enrollment resumed.

Key Takeaways

• Lonvo-z Phase III HAELO trial demonstrated an 87% reduction in mean monthly attacks versus placebo over six months, with 62% of treated patients attack-free and therapy-free.
• All patients receiving lonvo-z showed attack rate reductions from baseline; benefits were consistent across demographics and prior therapy status.
• The rolling BLA submission for lonvo-z is underway, with FDA acceptance expected by year-end and a potential U.S. launch in the first half of next year.
• Nex-z Phase III trials for ATTR resumed in Q2 after resolving clinical holds, with investigator engagement and screening rates improving globally.
• Management highlighted the large unmet needs in the ATTR market and maintained confidence in combination therapy approaches despite recent negative trial results for a competitor’s silencer agent.